[Forthcoming paper, Summer 2013, Currents International Trade Law Journal] Abstract: Countries may choose various methods of data protection in order to comply with the TRIPS Agreement. Policymakers should consider the effects of data exclusivity on prices and investment relative to other types of data protection. The data presented here suggest there is no relationship between whether or not a country has data exclusivity, and the amount of investment in the country by the pharmaceutical industry. On the other hand, empirical evidence in previous papers has shown that data exclusivity does drive prices higher.
Full paper available on SSRN at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2259797
